Background: We examined the relationship between the response to treatment and
Introduction
The treatment policy for aggressive lymphoma is determined based on the International Prognostic Index (IPI) 1) , Cotswolds Modification of the Ann Arbor Staging System 2) , and patient's condition. Patients with localized aggressive lymphoma can be cured with systemic chemotherapy and/or radiotherapy. The CHOP regimen (consisting of a combination of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone) is generally the first choice for chemotherapy 3) with and without consolidative radiotherapy 4) . However, the usefulness of rituximab (anti-CD20 monoclonal antibody)
has been reported and R-CHOP (CHOP + rituximab) has been adopted for chemotherapy 5) . With these standard treatments, the cure rate of patients with all stages of aggressive lymphoma is about 40%. However, there are limits to predicting the outcome based on IPI score, and further prognostic predictors during treatment leading to early changes in therapy may improve outcome and survival.
With regard to the role of imaging diagnosis of malignant lymphoma, imaging evaluation contributes to not only differential diagnosis but also to the initial staging for determining the optimum treatment strategy and evaluation of the effects of treatment.
The International Workshop to Standardize Response Criteria based on computed tomography (CT) have been widely used for response assessment of Non-Hodgkin's lymphoma (NHL) 6) . CT and Gallium scintigraphy (Ga-67) are generally used for evaluation of the effects of treatment in patients with NHL. Magnetic resonance imaging (MRI) and positron emission tomography (PET) are also used in special situations. However, the values of these modalities for clinical usage are still controversial. This raises questions of how best to make use of the results of CT, MRI, and Ga-67 to make changes to the treatment strategy.
We evaluated the relationship between the response to treatment evaluated by radiographic imaging and prognosis of patient with aggressive lymphoma.
Material and Methods:
We reviewed 33 patients with aggressive lymphoma treated with chemotherapy CT was performed with a slice thickness of 5mm before and after the intravenous injection of contrast medium. MRI was performed with a 1.5-T unit using spin-echo technique. T1-weighted images were acquired axial images. Axial T2-weighted fat-suppressed images were also obtained. . Complete response (CR) was defined as complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms. Previously involved nodes or nodal masses on CT or MRI more than 1.5 cm in largest diameter must regress to less than 1.5 cm and previously involved nodes/nodal masses of 1.1 to 1.5 cm must regress to less than 1.0 cm. Partial response (PR) was defined as a reduction of at least 50% in the sum of the product of the greatest diameters of the six largest dominant nodes or nodal masses with no increase in the size of other nodes and with no new sites of disease. Stable disease (SD) was less than PR but not progressive disease (PD). PD was defined as a 50% increase in the sum of the product of the greatest diameters from the nadir of any previously identified abnormal node for PR and non-responders, or the appearance of any new lesion during or at the end of therapy.
Ga-67-based determinations of CR, SD, and PD were defined as complete disappearance of accumulation, equal accumulation, and increased accumulation as compared with before treatment, respectively.
Statistical analysis
Survival was measured from the first day of treatment. Death from any cause was included as an event in the overall survival, and any failure and any cause of death were included as events in the progression-free survival. The overall and progression-free survival curves were calculated using the Kaplan-Meier method 8) . Differences between the survival rates were tested for statistical significance by the generalized Wilcoxon test. Statistical significance for all analyses was set at p < .05.
Results
After completion of treatment, 21 patients (64%) achieved CR, 7 patients (21%) achieved PR, and 5 patients (15%) developed PD of the 28 patients showing CR and PR, 21 showed no progression, while the remaining 7 did show progression. One patient had relapse at local progression and 6 patients showed relapse at lymph nodes outside the area of the primary lesion.
The 2-year overall and progression-free survival rates were 72% and 63%, respectively The 2-year progression-free survival rate in patients in whom Ga-67 uptake had disappeared at completion of chemotherapy was 80%, while that in patients in whom uptake remained was 26% (p = .001) (Figure 2 ).
Discussion
Aggressive lymphomas are a heterogeneous group of diseases that are various with regard to histopathology, clinical behavior in response to therapy, and outcome. In contrast to many solid tumors, lymphomas are highly sensitive to chemotherapy and radiotherapy, and about 50-60% of patients with aggressive lymphoma achieve prolonged survival and cure 9, 10) . In the present study, 21 of 33 patients (63%) with aggressive lymphoma achieved disease-free survival for the duration of the study.
In the past, determination of the effects of treatment for malignant lymphomas is based on CT 6)
. However, there are limitations in assessment of response to therapy by CT [11] [12] [13] [14] [15] , and Ga-67, FDG-PET, and MRI have been reported to be useful for detection of lesions. MRI is particularly useful in identifying bone and CNS involvement. MRI can suggest leptomeningeal involvement when gadolinium has been used. MRI can also be used to identify bone marrow involvement 16) . In contrast, CT and MRI often show a residual mass, which may not be neoplastic. In clinical CR patients treated with chemotherapy and/or radiation, only 10-18% of residual masses detected by CT and/or MRI are viable tumors 17, 18) . In cases in which residual masses were detected by CT or MRI, it was difficult to discriminate between a viable tumor, necrosis, and fibrosis. The response to treatment of aggressive lymphoma is heterogeneous, even in patients with the same histological findings. Ga-67 and FDG-PET findings are indicators of cancer cell viability and can be used to monitor the response of the tumor cells in each patient to the particular course of chemotherapy received. In Hodgkin's lymphoma and aggressive or highly aggressive lymphoma, Ga-67 and FDG-PET may prove particularly useful in detecting residual disease [11] [12] [13] [14] [15] [19] [20] [21] . It has been shown previously that Ga-67 performed at the end of chemotherapy is superior to CT in patients with both
Hodgkin's lymphoma and NHL for monitoring the response to treatment 12, 22, 23) .
After patients have completed the entire planned treatment regimen, reevaluation should be done to determine the response to therapy. Achieving complete remission to therapy is the most important single prognostic factor in patients with NHL. Salvage treatment, such as high-dose therapy and autologous or allogeneic bone marrow transplantation, can sometimes cure disease in patients who fail to respond to initial therapy 24) . In the relationship between treatment effect and prognosis, patients who react early to chemotherapy are predisposed to accomplish a high CR rate 25, 26) . Kaplan et al. 11) reported Ga-67 imaging to be an excellent indicator of residual viable tumors early during chemotherapy in 37 patients with diffuse large B-cell lymphoma. At follow-up, 59% of the patients who were Ga-67 positive halfway through therapy died, whereas in the group of negative patients only 20% died due to disease progression. Front et al. 12) compared the disease-free survival between patients with positive or negative Ga-67
and CT scan. CT findings were not predictive of outcome in contrast to Ga-67 imaging.
In the present study, the correlation between progression-free survival and response after completion of chemotherapy was stronger in determination by Ga-67 than by CT.
The value of FDG-PET in the assessment of lymphoma has been investigated.
FDG-PET combines the advantages of nuclear medicine techniques, such as Ga-67, as an indicator of tumor viability with improved resolution and higher sensitivity, and these advantages lead to higher lesion detection efficiency. In cases in which the persistence of accumulation was seen with FDG-PET after 1 cycle of chemotherapy for
Hodgkin's and non-Hodgkin's lymphoma, prognosis was wrong 15, 27, 28) . On the other hand, in cases with disappearance of accumulation after one cycle of chemotherapy, the recurrence rate was reduced. Similarly, early interim FDG-PET is an accurate and independent predictor of progression-free survival and overall survival [29] [30] [31] [32] [33] [34] [35] . All studies published to date suggested increased sensitivity of FDG-PET as compared with other imaging modalities, including Ga-67, when used for lymphoma staging [36] [37] [38] [39] . Such findings provided rationale for incorporating FDG-PET into revised response criteria for malignant lymphoma [40] [41] [42] . PET is strongly recommended before treatment for patients with routinely FDG-avid, potentially curable lymphomas to better delineate the extent of disease. In addition, FDG-PET is essential for the post-treatment assessment of diffuse large B-cell lymphoma and Hodgkin's lymphoma 42) . Although it has been shown that Ga-67 and FDG are both viable agents and that they show similar behavior in lymphoma after treatment, FDG-PET has significantly higher cost and more complicated logistics than Ga-67. Just now Ga-67 scan should be used as alternative of PET in hospitals where it has not been set up.
The results of the present study suggest that FDG-PET and Ga-67 scintigraphy are an efficient method for predicting the outcome of individual patients with aggressive lymphoma. Patients with abnormal FDG-PET or Ga-67 uptake after chemotherapy may need to receive additional treatment modifications. Effort is now being made to improve the outcome in patients who do not achieve complete response, including modification of dose intensity, use of autologous stem cell transplantation, and multiple new agents.
Further studies are required to determine whether early selection with FDG-PET or Overall and progression-free survival curves of all patients
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Progression-free survival curves according to the findings of Gallium scintigraphy after completion of chemotherapy 
